Sunday 11 October 2026 Export all AZN data to Excel Powerpack

AstraZeneca PLC

AZN Healthcare Drug Manufacturers General

AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024. In the quarter to June 2026, revenue grew 6.41%, EPS grew 1.90%, free cash flow fell 107.5% and total debt fell 5.50%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five; insiders bought in the last twelve months.

159.20 0.42 +0.26%
Market cap
$246.3B
P/E
23.6×
Fwd P/E
23.4×
Dividend yield
2.02%
F-score
9/9
Altman Z
6.26
Beneish M
−2.51
Dividend safety
54/100
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
19.94 29.73 44.68 94.08 40.64 388.33 64.79 35.44 28.74 27.86
Piotroski F-Score
6 3 4 6 7 5 7 7 6 9
P/S ratio
3.05 3.99 4.36 5.32 4.93 4.42 4.84 4.63 7.51 9.70
Altman Z-Score
1.68 1.80 1.90 2.23 2.29 1.95 2.65 2.70 4.71 6.26
Altman Z″-Score (non-manufacturers)
1.12 0.85 0.92 0.52 1.03 0.97 0.65 0.90 1.30 1.80
P/FCF ratio
20.99 26.22 26.76 49.48 40.36 37.86 26.95 30.32 54.50 64.63
Beneish M-Score
(2.74) (2.48) (2.54) (2.59) (2.40) (2.20) (2.75) (2.58) (2.59) (2.51)
P/Operating CF
35.77 89.85 43.27 94.35 72.96 116.50 89.51 89.04 139.74 243.37
Dividend Safety Score
— — — — — — — — — 54
P/B ratio
4.21 5.38 6.85 8.89 8.39 4.20 5.79 5.41 9.94 11.70
Price to Tangible BV
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Sales
3.52 4.58 4.95 5.78 5.36 5.04 5.33 5.09 7.94 10.08
EV/EBITDA
11.16 15.31 15.32 21.09 17.17 24.85 25.60 17.18 25.72 30.39
EV/Operating CF
19.54 28.73 41.79 47.50 29.74 31.61 24.11 22.55 36.20 40.61
EV/FCF
24.25 30.09 30.42 53.79 43.92 43.21 29.68 33.38 57.61 67.12
Quick Ratio
0.72 0.62 0.72 0.68 0.76 0.74 0.67 0.64 0.74 0.72
Current Ratio
0.87 0.80 0.96 0.86 0.96 1.16 0.86 0.82 0.93 0.94
Net Debt/EBITDA
1.50 1.97 1.85 1.69 1.39 3.07 2.36 1.58 1.39 1.13
Debt/Assets
26.88% 28.11% 31.51% 28.60% 29.52% 28.28% 29.31% 27.19% 27.72% 24.39%
Debt/Equity
1.01 1.07 1.36 1.20 1.26 0.76 0.76 0.70 0.71 0.57
Asset Turnover
0.38 0.36 0.36 0.40 0.42 0.43 0.44 0.46 0.53 0.54
Operating CF/Net income
1.18 1.19 1.21 2.22 1.50 53.24 2.98 1.74 1.69 1.43
Capex/Depreciation
(0.34) (0.05) 0.26 (0.09) (0.49) (0.24) (0.34) (0.62) (0.66) (1.00)
Interest Coverage
3.54 2.44 2.39 2.04 3.95 0.81 2.79 5.04 5.74 8.11
ROE
19.89% 18.02% 14.05% 9.32% 21.14% 0.41% 8.61% 15.63% 17.58% 22.83%
ROA
5.71% 4.77% 3.48% 2.19% 4.99% 0.13% 3.26% 6.03% 6.86% 9.38%
ROIC
11.12% 7.69% 7.78% 7.06% 11.86% 1.05% 3.99% 8.45% 9.77% 12.15%
Return on Tangible Assets
72.08% 68.48% 32.07% 26.00% 42.68% 0.87% 68.40% 152.15% 85.66% 92.38%
Average Days of Receivables
79.33 89.90 95.52 90.50 101.28 100.54 92.60 107.98 100.11 101.50
Research and Development Expense of Revenue
25.61% 25.63% 26.85% 24.85% 22.51% 26.02% 22.01% 23.87% 25.12% 24.23%
Selling, General and Administrative Expense of Revenue
42.34% 46.93% 46.91% 49.30% 43.93% 41.91% 42.74% 43.12% 37.97% 34.92%
Intangible Assets out of Total Assets
0.63 0.60 0.56 0.53 0.49 0.59 0.61 0.57 0.56 0.52
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Graham Net Nets
(0.46) (0.37) (0.32) (0.24) (0.24) (0.24) (0.17) (0.17) (0.09) (0.06)
Graham Number
28.71 26.53 20.59 16.36 25.69 13.68 33.95 46.86 36.78 48.31
Earnings Yield
5.02% 3.36% 2.24% 1.06% 2.46% 0.26% 1.54% 2.82% 3.48% 3.59%
Free Cash Flow Yield
4.76% 3.81% 3.74% 2.02% 2.48% 2.64% 3.71% 3.30% 1.83% 1.55%
Revenue per Share
18.18 17.74 17.43 18.74 20.29 26.39 28.65 29.57 17.44 18.95
Operating CF per Share
3.28 2.83 2.07 2.28 3.66 4.21 6.34 6.68 3.83 4.70
Capex per Share
(0.64) (0.13) 0.77 (0.27) (1.18) (1.13) (1.19) (2.17) (1.42) (1.86)
Free Cash Flow per Share
2.64 2.70 2.84 2.02 2.48 3.08 5.15 4.51 2.40 2.84
Cash per Share
4.69 3.62 4.69 4.81 6.20 4.57 4.19 3.92 1.84 1.88
Shareholders Equity per Share
13.18 13.15 11.08 11.22 11.92 27.71 23.94 25.28 13.18 15.72
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
13.18 13.15 11.08 11.22 11.92 27.71 23.94 25.28 13.18 15.72
Free Cash Flow
3,340.00 3,417.00 3,597.00 2,622.00 3,250.00 4,363.00 7,966.00 6,990.00 7,453.00 8,819.00
Working Capital
(1,994.00) (3,233.00) (701.00) (2,554.00) (763.00) 3,650.00 (3,700.00) (5,488.00) (2,039.00) (1,894.00)
Capital Expenditures
(805.00) (161.00) 979.00 (347.00) (1,549.00) (1,600.00) (1,842.00) (3,355.00) (4,408.00) (5,756.00)
Net Current Asset Value
(32,595.00) (33,562.00) (31,016.00) (31,218.00) (31,547.00) (39,832.00) (36,832.00) (36,899.00) (37,337.00) (36,632.00)
EV/EBIT
16.52 27.96 32.30 48.23 27.65 178.51 62.93 28.48 42.92 43.07
Capex to Sales
0.04 0.01 (0.04) 0.01 0.06 0.04 0.04 0.07 0.08 0.10
Price to Operating Income
14.30 24.36 28.41 44.37 25.41 156.44 57.13 25.86 40.61 41.47
Other line items
Depreciation/Fixed assets
0.34 0.40 0.51 0.49 0.38 0.71 0.64 0.57 0.65 0.44
Cash ROIC
8.48% 8.75% 9.20% 6.83% 7.48% 5.77% 11.09% 9.61% 9.88% 10.71%
Accounts Receivable Turnover
3.83 4.27 3.90 4.12 3.96 4.23 4.11 3.69 3.81 3.77
Accounts Payable Turnover
0.37 0.39 0.40 0.37 0.36 0.72 0.65 0.40 0.46 0.45
Inventory Turnover
1.84 1.61 1.67 1.62 1.47 1.91 1.81 1.63 1.91 1.80
Average Days of Payables
927.63 984.01 949.55 1,037.44 1,087.29 555.79 560.86 987.73 803.34 867.79
Days of Inventory on Hand
206.47 256.55 213.71 236.83 277.18 263.63 138.42 239.45 189.10 225.08
Average Receivables
6,004.00 5,266.00 5,657.00 5,913.50 6,716.00 8,846.50 10,779.50 12,402.00 14,191.50 15,583.00
Average Payables
11,074.50 11,063.50 12,241.00 13,414.00 14,886.00 17,361.50 18,989.00 20,707.00 22,419.50 23,872.50
Average Inventory
2,238.50 2,684.50 2,962.50 3,041.50 3,608.50 6,503.50 6,841.00 5,061.50 5,356.00 5,922.50
Average Assets
61,291.00 62,940.00 62,002.50 61,014.00 64,053.00 86,046.00 100,923.00 98,801.00 102,577.00 109,054.50
Average Common Equity
17,589.00 16,655.50 15,343.00 14,320.00 15,117.00 27,462.50 38,172.50 38,112.00 40,018.50 44,795.00

Fold the line items

Columns are period end dates